Edith Cowan University

Research Online
Research outputs 2022 to 2026
1-1-2022

Impact of converging sociocultural and substance-related trends
on US autism rates: Combined geospatiotemporal and causal
inferential analysis
Albert Stuart Reece
Edith Cowan University, s.reece@ecu.edu.au

Gary Kenneth Hulse
Edith Cowan University, g.hulse@ecu.edu.au

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Chemicals and Drugs Commons
10.1007/s00406-022-01446-0
Reece, A. S., & Hulse, G. K. (2022). Impact of converging sociocultural and substance-related trends on US autism
rates: Combined geospatiotemporal and causal inferential analysis. European Archives of Psychiatry and Clinical
Neuroscience, 1-19. Advance online publication. https://doi.org/10.1007/s00406-022-01446-0
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/952

European Archives of Psychiatry and Clinical Neuroscience
https://doi.org/10.1007/s00406-022-01446-0

ORIGINAL PAPER

Impact of converging sociocultural and substance‑related trends
on US autism rates: combined geospatiotemporal and causal
inferential analysis
Albert Stuart Reece1,2

· Gary Kenneth Hulse1,2

Received: 9 November 2021 / Accepted: 7 June 2022
© The Author(s) 2022

Abstract
Whilst cannabis is known to be toxic to brain development, it is unknown if it is driving rising US autism rates (ASMR). A
longitudinal epidemiological study was conducted using national autism census data from the US Department of Education
Individuals with Disabilities Act (IDEA) 1991–2011 and nationally representative drug exposure (cigarettes, alcohol, analgesic, and cocaine abuse, and cannabis use monthly, daily, and in pregnancy) datasets from National Survey of Drug Use
and Health and US Census (income and ethnicity) and CDC Wonder population and birth data. Analysis was conducted in
R. 266,950 were autistic of a population of 40,119,464 8-year-olds in 1994–2011. At national level after adjustment, daily
cannabis use was significantly related to ASMR (β estimate = 4.37 (95%C.I. 4.06, 4.68), P < 2.2 × 10–16) as was first pregnancy
trimester cannabis exposure (β estimate = 0.12 (0.08, 0.16), P = 1.7 × 10–12). At state level following adjustment for cannabis,
cannabigerol (from β estimate = – 13.77 (– 19.41, 8.13), P = 1.8 × 10–6) and Δ9-tetrahydrocannabinol (from β estimate = 1.96
(0.88–3.04), P = 4 × 10–4) were significant. Geospatial state-level modelling showed exponential relationship between ASMR
and Δ9-tetrahydrocannabinol and cannabigerol exposure. Exponential coefficients for the relationship between modelled
ASMR and Δ9-tetrahydrocannabinol and cannabigerol exposure were 7.053 (6.39–7.71) and 185.334 (167.88–202.79; both
P < 2.0 × 10–7). E-values are an instrument related to the evidence for causality in observational studies. High E-values were
noted. Dichotomized legal status was linked with elevated ASMR. Data show cannabis use is associated with ASMR, is
powerful enough to affect overall trends, and persists after controlling for other major covariates. Cannabinoids are exponentially associated with ASMR. The cannabis–autism relationship satisfies criteria of causal inference.
Keywords Cannabis · Cannabinoid · Δ9-tetrahydrocannabinol · Cannabigerol · Pathways and mechanisms

Introduction
It is well known that the incidence of autistic spectrum disorder is increasing in the USA, with current annual rates
as high as 1.68% being reported nationwide by Centers for
Disease Control, Atlanta, Georgia (CDC) [1]. Indeed up to
4.5% of 8-year-old boys in New Jersey have been diagnosed
with this disorder [1]. For reasons which are unclear, the
syndrome is more common in boys than girls perhaps related
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to the many extra neurological genes on the X-chromosome,
which is randomly inactivated in females thereby providing
a wider range of spare alleles from which to support neurological development [2].
Whilst the literature identifies several causes which contribute to the incidence of autism, including obesity, maternal diabetes, advanced parental age, twin linkage, bleeding,
having another autistic sibling, higher income, and exposure
to some drugs including cannabinoids [3–7], the primary
drivers of the present surge have remained largely elusive.
Of concern, all three longitudinal studies of brain development following prenatal cannabis exposure (PCE) have
identified adverse neurological outcomes mimicking attention deficit hyperactivity disorder (ADHD) and autistic spectrum features [8]. At a time of major commercialization of
the cannabis industry, such findings must be of particular
concern.

13

Vol.:(0123456789)

European Archives of Psychiatry and Clinical Neuroscience

It is of interest that a recent population-wide study of all
births in Ontario 2007–2012 using coarsened exact matching
and controlling for a wide variety of socioeconomic, medical, maternal age, maternal psychiatric, other substance use,
and obstetric covariates found a 51% higher adjusted rate
of autistic spectrum disorders (adjusted hazard ratio = 1.51
(95% CI 0.17–1.96)) following cannabis-exposed pregnancies which was invariant across all socioeconomic strata [9].
Because these syndromes are not usually identified prior
to the age of 8 years, there is inevitably a lengthy delay in
reporting the current state of the epidemic.
At the time of conducting our analysis, we were aware
that drug exposure was highly correlated to ethnocultural
factors and that PCE was known to be rising across USA.
It was felt to be important to take such considerations into
account in conducting our analysis.
Our primary hypothesis was that increasing substance
and/or cannabinoid exposure might constitute a primary
underlying driver of US autism rate (ASMR) across time.
This hypothesis was formulated prior to data analysis. We
wished to explore the effects and relative contribution of
external demographic and socioeconomic covariates in a
formal geotemporospatial framework.

Methods
Data sources
State autism rates were derived from the US Department
of Education Individuals with Disabilities (IDEA) database
[10]. State population data from the US Census Bureau
were used to calculate national rates. State population,
ethnicity and median household income data was sourced
from US Census via the tidycensus package in “R” from
Comprehensive “R” Archive Network (CRAN). Data on
national age of child-bearing was sourced from the births
registries of the CDC Wonder website [11]. Drug use data
in various demographic subgroups and in pregnancy was
taken from the nationally representative National Survey of
Drugs and Health (NSDUH) conducted each year by the
Substance Abuse and Mental Health Services Administration (SAMHSA) and particularly from the online interactive
Substance Abuse and Mental Health Data Archive (SAMHDA [12]). Data on national cannabinoid concentrations
was from Drug Enforcement Agency [13, 14]. Missing data
were casewise deleted in linear (lm) and panel (plm) regression except where otherwise described.
State cannabinoid exposure estimates were derived by
multiplying the monthly cannabis use rate by state by the
concentration of the various cannabinoids obtained in Federal seizures. Data on Δ9-tetrahydrocannabinol (Δ9THC),
cannabinol (CBN), cannabidiol (CBD), cannabigerol (CBG),
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cannabichromene (CBC) and tetrahydrocannabidivarin
(THCV) were available [13, 14].
Ethnicity was defined by SAMHSA and US Census.
These official definitions of ethnicity were used in analysis.

Statistics
This study was conducted in 2019. Data was processed using
“R Studio” version 1.2.5042 based on “R” version 4.0.0 [15].
All graphs were prepared in ggplot2 package [16] from the
tidyverse [17] and 3-D graphs were drawn in NCSS software
[18]. All graphs and tables are original and have not been
previously published elsewhere. Variables were log transformed as guided by the Shapiro test. Details of R-packages
used are provided in the online statistical methods. Mixed
effects models were performed using R package nlme using
State as a grouping variable weighted by inverse probability
weights as described below [19]. Two-step panel regression
was conducted for space–time panel data using package
plm [20, 21]. For panel regression the pooling model was
used, effect was over both space and time, random method
was that of Swarmy and the instrumental method was that
of Amemiya. These settings are required by the software
or were found on preliminary analyses to give optimal output precision. Geospatial links were constructed canonically using the poly2nb function from spdep [22]. Spatial
links were edited with Alaska and Hawaii elided (moved)
conceptually to Oregon and Washington and to California,
respectively, both to reflect sociocultural relationships and
to prevent areal zones with no spatial relationships which
complicates geospatial analysis. Generalized two-step geospatial regression was performed using the spreml function
from package splm [23, 24], including both spatial autocorrelation errors and spatial lags and random effects using the
error structure of Kapoor, Kelejian and Prucha and with the
method of Baltagi, Pfaffermayr, Jong and Song with initial
values of zeros (sem2srre) [25]. Model specification was
checked with Lagrange multiplier tests and models were
compared by their log-likelihood (logLik) ratios at model
optimization using the spatial Hausman test (sphtest). Model
reduction was by the classical technique with sequential
deletion of the least significant term.
Two-step regression is a powerful well-established technique which utilizes instrumental variables that are thought
to more accurately reflect the real situation underlying the
listed covariates. It has been used in panel and geospatial
models in this report due to overwhelming evidence (presented below) of very different cannabis use patterns by
ethnicity to more accurately explore the underlying drug
exposure relationships.
Predicted fitted values from final models were calculated
by matrix multiplication inserting appropriate values alongside matching model terms.
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Causal inference
Inverse probability weighting (IPW) was conducted
using the R package ipw [26]. IPW values were calculated using the last month cannabis use as the exposure of
interest in a time-dependent manner. The numerator was
a series of additive terms including four drug variables
excluding cannabis exposure, four ethnicities, median
household income and five ethnic cannabis exposure
terms. The denominator included this list together with
monthly cannabis exposure. Interactive models included
a four-way interaction between tobacco, alcohol, cannabis and analgesic consumption. Weight truncation was
not required. All mixed effects and robust models were
inverse probability weighted. Robust generalized linear
regression was performed in the survey package (using
svyglm) with State as the grouping variable utilizing the
IPW weights [27].
EValue determination was performed using the R package EValue [28–30]. As eValue estimation of regression
coefficients requires a model standardized deviation, this
could not be performed on svyglm models; it was performed instead on mixed effects models structured and
weighted similarly to the svyglm models.
P < 0.05 was considered significant.

Results
Input data
The national rate of autistic spectrum disorder was derived
from the IDEA database combined with state population
data obtained from US Census and used to compute national
rates of autism. It was combined with other data as shown
in eTable 1 and graphed in eFigure 1. The IDEA dataset
for the 50 US states was almost complete for the 18 years
1994–2011. Only five data points were missing for this
period: New Hampshire in 1994, Montana 2006, Vermont
in 2007 and 2008, and Wyoming 2010 and these were filled
by temporal kriging (mean substitution). This dataset comprehended 266,950 autistic children of a total US population
of 40,119,464 8-year-olds, a mean rate of 66.5/10,000, for
the period 1994–2011.
Since the IDEA database began in 1991 and terminated
in 2011, it was extended through to 2018 using conservative
published national projections [31] which are actually below
the most recent CDC estimate (1.31% in 2014 v. 1.68% in
[1]). Data on cannabis use by ethnic group, daily cannabis
smoking and cannabis use in pregnancy was only available
from SAMHSA at the national level, which indicated that
these variables needed to be analysed at the national level.
Authoritative and nationally representative surveys have

shown repeatedly that rates of cannabis use in pregnancy
closely parallel those in the general community [32–38].
Figure 1 presents a sequential map series showing the
progress of autism across USA 1992–2011.
Figure 2 presents a bivariate map series of the autism rate
together with the cannabis use rate and one notes that both
are elevated in the northeast and northwest of the country
(pink and purple areas).
Figure 3 presents a similar bivariate map of USA showing autism and cigarette use plotted together. As cigarette
use declines, this map appears to be “turning bluer” than
the previous map.
The United Nations 2019 World Drug Report clearly
demonstrates that recent American use of cannabis relates
primarily to increased daily use [39]. SAMHSA provide
data that stratify the monthly frequency of cannabis use
into groups as non-user, 1–2 days, 3–5 days, 6–19 days and
20–30 days shown in eFigure 2. The confidence intervals are
taken directly from SAMHDA. Again, one notes that AsianAmericans smoke less cannabis 20–30 days per month and
more are non-users. Using the midpoint of these daily intervals as a multiplicand, it is possible to calculate the mean
daily use of each ethnic group over time with the results
shown in Fig. 4 and eFigures 2 and 3. Clear differences in
mean daily cannabis use by ethnicity are evident.
As disclosed by United Nations Office of Drugs and
Crime (UNODP), the pattern of cannabis use matters. SAMHDA data show that in 2017 about 92.6% of Americans
smoked cannabis to a trivial extent (≤ 3 days/month) and
7.35% smoked ≥ 3 days/month (eTable 2).
These data allow the calculation of an Ethnic Cannabis
Exposure Score which can be plotted against a State–Time
index and against time (eFigure 4A and 4B). These data
show that without exception in each state, the Ethnic Cannabis Exposure Score rose across time. The red line in the
centre of Panel B shows the median trajectory as a loess
curve of best fit.

Regression results
Linear regression was used to investigate the association
between daily cannabis use and ethnicity. The covariates
were time and ethnicity. eTable 3 shows the results in a
model quadratic in time and confirms highly significant differences in cannabis use by ethnicity (from β estimate = 1.67
(95% CI 1.45–1.89), P < 2.2 × 10–16; quadratic superior to
linear model, ANOVA F = 2.147, df = 13, P = 0.019).
eFigure 5 shows that high intensity cannabis use is falling
amongst teenagers, but rising in older age groups. eFigure 6
confirms these age-dependent trends in the first trimester of
pregnancy which shows more cannabis use than later trimesters. eFigure 7 has been drawn from CDC birth data
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Fig. 1  Map sequence of autism rates across USA selected years 1992–2011. Data from IDEA Dataset in reference 4
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Fig. 2  Bivariate choropleth maps of the relationship between autism and cannabis use over time
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Fig. 3  Bivariate choropleth maps of the relationship between autism and cigarette use over time
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Quantitative Cannabis Exposure in Each Pregnancy Trimester Over Time
USA, NSDUH, SAMHSA
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Fig. 4  Plots of cannabis use in each pregnancy trimester over time. Data from SAMHDA from SAMHSA

and confirms the trend of childbirth to be occurring at older
maternal ages. In the light of the findings of eFigure 5, this
implies that these women are moving up into a higher cannabis use age bracket.
Figure 5 presents the mean data for cannabis use by pregnancy trimester for all age groups and confirms that first
trimester cannabis use is rising with time, a trend not seen at
later trimesters. The SAMHSA data for 2015 is incomplete,
so this point has been filled by mean substitution (0.027).
The correlation between time and the rising use of cannabis
in pregnancy is R = 0.6115 (P = 0.001). The slope of the first
trimester regression line is significantly different to that in
the third trimester (β estimate = – 4.97 × 10–8 (– 8.44E-08
to – 1.5E-08), P = 0.007, model Adj. R2 = 0.174, F = 4.31,
df = 3.44, P = 0.009).
These data invite exploration by regression analysis.
Panel regression was utilized as time is an implicit variable
rather than an explicit one (important in small data tables),
and one can easily include both temporal lags and instrumental variables in the R package plm. Only a limited number of variables can be included because of the small number
of observations. The Ethnic Cannabis Exposure Score was
multiplied by the THC Potency to capture the effect of rising
THC concentrations. The variable was called the “Ethnic
Cannabis Score THC Potency”. Cigarettes, the cannabis
index, analgesics, three races and median household income
have been included as covariates for 1994–2018. When the
regression is performed for the national autism rate in this
manner the results indicated in Table 1 are obtained. A very

high level of statistical significance of all the variables is
noted (all P < 2.2 × 10–16).
Panel regression may also be used to model the relationship between ASMR and first trimester cannabis use.
The covariates in this model were first trimester cannabis
use, THC potency, median household income, cocaine
and analgesic use, and the three most common races
(Caucasian-American, African-American and HispanicAmerican). This model has one interaction between first
trimester cannabis use and THC potency and 2 years of
lag. The instrumental variables along with the highly significant results are listed in Table 1.

Robustness analysis
A robustness analysis on these data using published high
and low estimates of the national autism rate for 1994–2018
derived from projections from states where cannabis was
illegal and those where it was legal, respectively [31], confirmed these conclusions (eTable 4).

Geospatial regression
Naturally, we were interested to explore if these relationships
extended to an analysis at state level. eFigure 8 sets out the
geospatial links and weights used.
Geospatial regression was performed in 2002–2011 with
results shown in eTable 5 using five drugs—cigarettes,
alcohol abuse, monthly cannabis, misuse of analgesics,
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Data − NSDUH, SAMHSA, 2002−2017, with Narrow and Wide Confidence Intervals
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Fig. 5  Mean cannabis use by ethnicity. Data from SAMHDA from SAMHSA
Table 1  National panel regression model results
Instrumental ± lagged variables

General population model
2 lags, 1 interaction
Lag (Cannabis_Monthly), 0:2
Lag (Δ9THC_Exposure), 0:2
Lag (Cannabigerol_Exposure), 0:2
Cocaine_Annual

First trimester pregnancy exposure
2 lags, 1 interaction
Lag(First_Trimester_Cannabis_Exposure), 0:2
Lag(THC_Potency), 0:2
Lag(White_Ethnicity), 0:2
Lag(Hispanic_Ethnicity), 0:2

Parameter

Parameter

Cigarettes_Monthly
African-American_Ethnicity
Ethnic_Cannabis_Score_THC_Potency
Hispanic_Ethnicity
Median_Household_Income
Non-Medical_Use_of_Analgesics
Caucasian-American_Ethnicity
Cigarettes_Monthly: Ethnic_Cannabis_Score_
THC_Potency

First_Trimester_Cannabis_Exposure: THC_Potency
Caucasian-American_Ethnicity
First_Trimester_Cannabis_Exposure
Cocaine_Annual

estimate CI

P value

31.83 (29.79–33.87)
11.15 (10.6–11.7)
4.37 (4.06–4.68)
0.83 (0.77–0.89)
1.5E-05 (1.4E-05–1.6E-05)
– 2.98 (– 3.3–2.7)
– 14.79 (– 15.3–14.3)
– 18.65 (– 19.9–17.4)

< 2.2e-16
< 2.2e-16
< 2.2e-16
< 2.2e-16
< 2.2e-16
< 2.2e-16
< 2.2e-16
< 2.2e-16

– 0.06
– 6.19
0.12
0.25

(– 0.08–0.04)
(– 7.07–5.31)
(0.08–0.16)
(0.15–0.35)

< 2.2e-16
< 2.2e-16
1.7E-12
3.9E-08

0:2 represents 0–2 years temporal lag, THC tetrahydrocannabinol, Δ9THC Δ9- tetrahydrocannabinol, CI 95% confidence interval

cocaine—and the five races—Caucasian-American, African-American, Hispanic-American, Asian-American and
American Indians and Alaskan Natives—and median household income were considered as covariates, and instrumental variables were used for monthly cannabis use, Δ9THC
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and cannabigerol and the annual Ethnic Cannabis Exposure Score was used to control for cannabis exposure arising in relation to ethnic origin. A three-way interaction
term included cigarettes, cannabis and opioids. As shown
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in eTable 5, significant results for cannabis were obtained
(from β estimate = 8.41 (3.08–13.74), P = 0.002) at 2 years
lag.
Clearly in such a study, one is concerned that ethnocultural factors relating to increased drug exposure in certain
communities might be acting in addition to ethnopharmacogenomic factors relating to different responses to, or
processing of, addictive drugs. To control at least in part
for this effect, we performed a further regression not with
the states’ racial composition, but with the Ethnic Cannabis
Exposure Score described above. The instrumental variable
list was similar to that described above. These results are
shown in eTable 6, where terms including cannabis are noted
to be significant (from β estimate = 10.88 (5.97–15.79),
P = 1.4 × 10–5) at 2 years lag, cannabis is independently significant alone (β estimate = 0.63 (0.13–1.13), P = 0.014) and
the Ethnic Cannabis Exposure Score is highly significant at
all lags (from β estimate = 0.17 (0.09–0.26), P = 4.6 × 10–5).
Finally, we were interested to learn if the inclusion of specific cannabinoids in the model would be significant when
race and median household income were included. Geospatial links were derived from the R spdep package and edited
as shown in eFigure 8A to achieve the final spatial links
shown in eFigure 8B. The regression results from spatial
two-stage and lagged models are shown in Table 2 with full
model details provided in eTable 7. Instrumental variables
included individual terms for ethnic cannabis exposure and
are indicated in the table. Terms including cannabinoids are
significant in an unlagged model (from β estimate = – 13.77
(– 19.41 to – 8.13), P = 1.8 × 10–6) and across all models
Δ9THC and cannabigerol are independently significant
(from β estimate = 1.96 (0.88–3.04), P = 4 × 10–4 and β estimate = 0.81(0.34–1.28), P = 9 × 10–4). Spatial Hausman tests
confirm that the unlagged model is superior to models lagged
to 2 and 4 years (ChiSq. = 66.879, df = 9, P = 3.21 × 10–11
and ChiSq. = 626.46, df = 9, P = 8.744 × 10–129).
It was also of interest to consider the outcome if ethnic
cannabis exposure terms were included as covariates in the
model and no instrumental variables were used at all. This
interesting and highly significant model is shown in the final
panel of Table 2. Δ9THC exposure and the Δ9THC: cannabigerol interaction are both significant as are five ethnic
cannabis exposure terms.

Effect size
The availability of a final (unlagged) geospatial model
allows modelling of cannabinoid effects and potentially the
calculation of an effect size. When minimal and maximal
values for THC and cannabigerol exposure are inserted into
this model, autism rates of 0.37 and 38.42, respectively, are
predicted, a variation of 102.72-fold. Similarly, ASMR at
each decile of cannabinoid exposure may be calculated as

shown in eTable 8 and Fig. 6. Steep rises with rising cannabinoid concentration are shown (top panels) which are
linear on log plots, thus implying exponential relationships
(middle panels) and to which tight-fitting regression lines
may be fitted for deciles 2–9 (lower panels). The exponential
regression coefficients for the relationship between ASMR
and THC and cannabigerol exposure for deciles 2–9 are
7.053 (6.39–7.71) and 185.334 (167.88–202.79) with both
P < 2.0 × 10–7 (eTable 9) and both Pearson correlation coefficients R > 0.992, P < 2.0 × 10–7.
As one doubles the THC exposure from 0.4 to 0.8 and to
1.6%% (compound units), the predicted ASMR rises from
0.022 to 0.382 to 107.83/10,000 children or 4,736.81-fold.
As the cannabigerol exposure rises from 0.02 to 0.04 to
0.08%%, the modelled ASMR rises from 0.059 to 2.43 to
4029.65/10,000 children, or 67,511.42-fold which reflects
the exponential relationship.
The THC–cannabigerol–autism rate relationship is
illustrated from different perspectives in the 3D plots of
eFigure 9.

Causal inference
In addition to geospatiotemporal modelling, this dataset
lends itself also to the techniques of formal causal inference
to investigate further the nature of the association between
cannabis exposure and autism.
Inverse probability weighting was conducted considering
the monthly use of cannabis as the key exposure of interest.
Although this was an observational ecological study, weighting the key exposure variable in this manner allows one to
achieve a quasi-randomized design. Robust regression was
conducted in the R package survey.
When a full list of the five drug variables, four ethnicities, median household income and five ethnic cannabis
exposures was included in the robust regression model, the
results are as shown in Table 3. In the additive model only
a single ethnicity, non-Hispanic Asian is significant. The
other five significant terms all include cannabis. Cannabis
exposure alone is significant (β estimate = 1.08 (0.63–1.54),
P = 2.90 × 10–5) and terms involving ethnic cannabis exposure are significant (from β estimate = 3.63 (2.94–4.34),
P = 5.9 × 10–13).
In a model including a four-way interaction term between
substance exposure terms tobacco–alcohol–cannabis–analgesics, 13 of 22 terms remaining in the final model included
cannabis. In five cases, this related to ethnic cannabis exposure. In eight cases cannabis exposure itself was significant
in interactive terms. Cannabis exposure alone was also significant (β estimate = 803.00 (326.72–1279.28), P = 0.0024).
When a similar exercise is conducted using mixed
effects models, qualitatively similar results were obtained
(eTable 10).
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Table 2  Geospatial state-based regression of autism rate by individual cannabinoids, race and income
General

Parameters

Instumental ± lagged variables

Parameter

Estimate

95% CI

P value

NHAsian Ethnicity
NHWhite Ethnicity
Cannabigerol: Alcohol_Abuse
Alcohol_Abuse
Cannabigerol
NHAIAN Ethnicity
cigmon: Cannabigerol: Alcohol_Abuse
Δ9THC
Cigarettes: Δ9THC
Δ9THC: Cannabigerol
Cigarettes: Δ9THC: Cannabigerol

0.43
2.01
– 13.77
– 44.35
0.81
– 0.04
8.91
4.59
– 16.23
0.94
– 3.39

(0.33–0.53)
(1.42–2.6)
( – 19.41 to – 8.13)
( – 65.89 to – 22.81)
(0.34–1.28)
( – 0.06 to – 0.02)
(2.79–15.03)
(1.41–7.77)
( – 28.64 to – 3.82)
(0.21–1.67)
( – 6.21 to – 0.57)

< 2.2e-16
1.5E-11
1.8E-06
5.5E-05
9.0E-04
0.002
0.004
0.005
0.010
0.011
0.018

NHAsian Ethnicity
NHWhite Ethnicity
Alcohol_Abuse
NHAIAN Ethnicity
Cannabigerol: Alcohol_Abuse
Δ9THC
Cannabigerol
Δ9THC: Cannabigerol
NHAfrican-American Ethnicity

0.42
1.95
– 43.92
– 0.06
– 11.24
1.14
0.81
0.25
0.08

(0.3–0.54)
(1.22–2.68)
( – 69.97 to – 17.87)
( – 0.1 to – 0.02)
( – 18.12 to – 4.36)
(0.36–1.92)
(0.22–1.4)
(0.03–0.47)
(0–0.16)

3.1E-12
1.2E-07
0.001
0.001
0.001
0.005
0.007
0.023
0.046

NHAIAN Ethnicity
NHAsian Ethnicity
NHWhite Ethnicity
Cannabigerol: Alcohol_Abuse
Δ9THC
Alcohol_Abuse
Cigarettes: Cannabigerol: Alcohol_Abuse
Cigarettes: Δ9THC
Cigarettes: Alcohol_Abuse

– 0.11
0.37
1.52
– 22.68
1.96
– 72.45
71.65
– 6.44
214.56

( – 0.13 to – 0.09)
(0.23–0.51)
(0.74–2.3)
( – 34.89 to – 10.47)
(0.88–3.04)
( – 114.28 to – 30.62)
(25.41–117.89)
( – 10.63 to – 2.25)
(56.98–372.14)

9.0E-15
1.9E-07
1.0E-04
3.0E-04
4.0E-04
7.0E-04
0.002
0.003
0.008

NHAIAN
Alcohol_Abuse
CBG: Alcohol_Abuse
Asian.Am.Cannabis
Cauc.Am.Cannabis
Hispanic.Am.Cannabis
NHAsian
AIAN.Am.Cannabis
Δ9THC
Afric.Am.Cannabis
NHWhite
Δ9THC:Cannabigerol

– 0.14
– 53.52
– 13.87
2.60
– 3.23
2.96
0.34
0.48
2.08
0.30
1.25
0.24

( – 0.17 to – 0.1)
( – 68.57 to – 38.47)
( – 17.85 to – 9.89)
(1.79–3.42)
( – 4.27 to – 2.19)
(1.99–3.93)
(0.22–0.45)
(0.32–0.65)
(1.23–2.92)
(0.15–0.45)
(0.55–1.94)
(0.06–0.41)

2.9E-14
3.2E-12
8.5E-12
4.3E-10
1.1E-09
2.2E-09
5.6E-09
7.1E-09
1.4E-06
8.8E-05
0.0004
0.0098

0 lags
Cannabis, monthly
Δ9THC
Cannabigerol
NHWhite_Score
NHBlack_Score
Hispanic_Score
NHAsian_Score
NHAIAN_Score

2 lags
cannabis, monthly, 0:2
Δ9THC, 0:2
Cannabigerol, 0:2
NHWhite_Score, 0:2
NHBlack_Score, 0:2
Hispanic_Score, 0:2
NHAsian_Score, 0:2
NHAIAN_Score, 0:2
4 lags
cannabis, monthly, 0:4
Δ9THC, 0:4
Cannabigerol, 0:4
NHWhite_Score, 0:4
NHBlack_Score, 0:4
Hispanic_Score, 0:4
NHAsian_Score, 0:4
NHAIAN_Score, 0:4
0 lags, 0 instrumental variables

NH non-Hispanic, Am American, NHAIAN non-Hispanic-American Indian/Alaskan-Native, 0:2 0–2 years temporal lag, Δ9THC
Δ9-tetrahydrocannabinol, CI 95% confidence interval, 0:4 0–4 years temporal lag
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Modelled Autism Rate by ..9THC
Exposure Decile

Modelled Autism Rate by Cannabigerol
Exposure Decile

25

Autism Rate / 10,000 Children

25

Autism Rate / 10,000 Children

Fig. 6  Modelled autism rate
by exposure to Δ9THC and
cannabigerol. A Linear. B Logarithmic and C regression plots
for Δ9THC and cannabigerol,
respectively
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The above findings using IPW show that cannabis appears
to be causally related to the autism rate. However, it is theoretically possible that some unidentified and unmeasured
confounding factor, which is correlated with both the exposure of interest and the outcome, might be confounding these
results in the background. The magnitude required of this

1.2

0.02

0.03

0.04

Cannabigerol Exposure Level

0.05

unknown dual correlation effect to obviate the present results
can be quantified using the eValue.
Table 4 lists a set of eValues calculated from some of the
main results of this study listed above. One notes that many
of these eValues are very high, especially those deriving
from spatial models. This implies that a significant degree
of unmeasured confounding is unlikely. This fits with the
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Table 3  Multivariable robust
regression models of autism rate

Parameter

Estimate

Additive
Hispanic.Cannabis
NHAIAN.Cannabis
NHAsian.Cannabis
Cannabis
NHAsian
NHWhite.Cannabis
Interactive
NHAsian
Cannabis
Cannabis: Analgesics
Analgesics
Cigarettes: Alcohol: Cannabis
Cigarettes: Alcohol: Cannabis: Analgesics
Cigarettes: Alcohol
Cigarettes: Alcohol: Analgesics
NHWhite.Cannabis
Alcohol: Analgesics
Cigarettes: Analgesics
Alcohol
Cigarettes
Alcohol: Cannabis: Analgesics
Cigarettes: Cannabis: Analgesics
Alcohol: Cannabis
Cigarettes: Cannabis

3.63
1.94
1.27
1.08
0.25
– 11.70
0.31
803.00
265.20
791.40
32,850.00
10,730.00
97,700.00
31,900.00
– 3.98
– 9688.00
– 2634.00
– 29570.00
– 7994.00
– 3244.00
– 886.60
– 9894.00
– 2689.00

CI

P Value

(2.94–4.34)
(1.34–2.55)
(0.81–1.73)
(0.63–1.54)
(0.13–0.37)
(– 16.61 to – 6.81)

5.9E-13
1.3E-07
2.3E-06
2.9E-05
2.0E-04
2.8E-05

(0.15–0.47)
(326.72–1279.28)
(105.46–424.54)
(302.96–1279.04)
(8008–57,792)
(2428.8–18,971.2)
(22,240–173,160)
(6812–56,988)
(– 7.12 to – 0.84)
(– 16393.2 to – 2986.8)
(– 4454.76 to – 805.24)
(– 49,788 to – 9412)
(– 13419.2 to – 2560.8)
(– 5435.2 to – 1044.8)
(– 1484.8 to – 289.2)
(– 16534.4 to – 3245.6)
(– 4477.52 to – 902.48)

0.0008
0.0024
0.0026
0.0032
0.0145
0.0160
0.0163
0.0184
0.0185
0.0080
0.0080
0.0071
0.0070
0.0069
0.0066
0.0063
0.0059

CI 95% confidence interval, NH non-Hispanic, NHAIAN non-Hispanic-American Indian/Alaskan-Native

highly significant findings obtained in many of the earlier
results, and particularly with the close geotemporospatial
relationships demonstrated earlier.
These 29 E-value estimates and lower bounds may be
listed consecutively as shown in Table 5. Since both E Value
lists are shown in descending order, this presentation disrupts the pairing structure shown in Table 4. From this table
it is observed that of the E-value estimates, 4 are infinite and
25/30 (83.3%) exceed 9 and so are in the high range [40]
and 26/30 (86.7%) are greater than 1.25 and thus exceed
the threshold of causality [29]. Similarly for the minimum
E-values, 1 is infinite, 22/30 (73.3%) exceed 9 and thus
are in the high range and 25/30 exceed 1.25 (83.3%) and
therefore cross the threshold for causal effects. Considering the descriptive statistics for these two data pairs, the
E-value estimates have a median of 5.97 × 108 (interquartile range (IQR) 17.97, 2.40 × 1065) and the lower bound of
the E-values has a median value of 1.07 × 104 (IQR 5.54,
6.51 × 1024). These are very high and very dramatic results
and effectively exclude a significant role for hypothetical
confounder covariates.
Finally, it has previously been shown that liberal legislative paradigms for cannabis are associated with elevated
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rates of autism [41]; however, this has not been confirmed
in the geospatial context. eFigure 11 shows the (log)
autism rate against time by legal status dichotomized as
illegal status v. liberal status. Table 6 sets out the result of
geospatial regression of the (log) autism rate against the
dichotomized legal status and confirms a highly significant
finding. This regression coefficient is associated with a
relative risk of 2.05 (95% CI 1.20, 3.49) and eValues of
3.51 and 1.70, which are clearly relatively high. These
E-values have been included in Table 5.

Discussion
The principal question addressed by the present study was
to explore the mystery of the remarkable rise in US autism
rate which has remained hitherto largely unexplained.
This study is an epidemiological investigation which uses
national panel and state-level geospatial regression to analyse ecological covariates of childhood autism across a
diverse range of domains including socioeconomic, ethnicity and drug exposure. A particular focus of this study
is on environmental exposure to cannabis and selected
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Table 4  eValues for major results from foregoing analyses
Parameter
Decile Estimates
THC_Decile
CBG_Decile
Mixed Effects Models
Additive
African.Am.Cannabis
Cannabis
NHAIAN.Cannabis
Interactive
Cigarettes: Cannabis: Cocaine
Cigarettes: Cannabis
NHWhite.Cannabis
Cigarettes: Cannabis: Analgesics:
Cocaine
Cigarettes: Cannabis: Analgesics
Alcohol: Cannabis: Cocaine
Alcohol: Cannabis
Alcohol: Cannabis: Analgesics:
Cocaine
Alcohol: Cannabis: Analgesics
Spatial Spreml Models
0 lags
THC
Cannabigerol
THC*Cannabigerol
Cigarettes: Cannabigerol: Alcohol
2 lags
THC
Cannabigerol
THC*Cannabigerol
4 lags
THC
THC*Cannabigerol
0 Lags, Zero Instrumental Variables
THC
Afrc.Am.Cannabis
Hispanic.Am.Cannabis
Asian.Am.Cannabis
AIAN.Am.Cannabis
THC: Cannabigerol

Table

β estimate (C.I.)

RR (95% CI)

eValues

eTable 9

7.0526 (6.37, 7.71)
185.33 (167.87, 202.79)

1.10E + 27 (3.26E + 24, 3.71E + 29)
Infinity (Infinity, Infinity)

2.19E + 27, 6.51E + 24
Infinity, Infinity

eTable 10 0.509099 (0.39–0.63)
0.393926 (0.30–0.49)
0.258642 (0.10–0.41)

1.011 (1.008, 1.014)
1.102 (1.064, 1.011)
1.006 (1.002, 1.009)

1.12, 1.10
1.10, 1.08
1.08, 1.05

eTable 10 3753.1 (1451.28–6054.92)
15,065.8 (5585.85–24,545.75)
2 (0.73–3.27)
1167.2 (409.64–1924.76)

6.1E + 51 (1.22E + 20, 3.04E + 83)
7.6E + 207 (2.2E + 77, Infinity)
1.06 (1.02, 1.11)
1.3E + 16 (4.7E + 04, 3.4E + 26)

1.22E + 52, 4.5E + 20
Infinity, 4.37E + 77
1.33, 1.18
2.5E + 16, 9.4E + 05

1.2E + 65 (2.0E + 22, 1.2E + 108)
2.9E + 136 (9.4E + 40, 9.3E + 2321)
Infinity (1.2E + 137, Infinity)
6.0E + 40 (2.3E + 09, 1.5E + 72)

2.4E + 65, 2.4E + 22
5.9E + 136, 1.88E + 41
Infinity, 2.4E + 137
1.2E + 41, 4.5E + 09

4717 (1593.82–7840.18)
9890.4 (2955.51–16,825.29)
38,348.6 (9877.05–66,820.15)
2955.3 (673.59–5237.01)

11,491.4 (2112.41–20,870.39) 3.6E + 158 (2.6E + 29, 5.2E + 287)

Infinity, 5.1E + 129

Table 2

4.58 (1.41, 7.76)
0.81 (0.33, 1.29)
0.94 (0.21, 1.67)
8.91 (2.80, 15.02)

1.92E + 15 (5.34E + 04, 6.93E + 25)
495.54 (12.81, 1.92E + 04)
1.38E + 03(5.30, 3.61E + 04)
4.82E + 29 (2.38E + 07, 9.75E + 49)

3.85E + 15, 1.07E + 04
990.59, 25.11
2.77E + 03, 10.07
9.65E + 29, 4.77E + 09

Table 2

1.14 (0.35, 4.31)
0.81 (0.23, 1.39)
0.25 (0.023, 0.46)

6.03E + 03 (14.51, 2.51E + 06)
480.0 (5.65, 4.07E + 04)
6.48 (1.29, 32.42)

1.21E + 04, 28.51
959.59, 10.78
12.44 1.91

Table 2

1.95 (0.87, 3.04)
71.65 (25.41, 117.88)

349.01 (13.73, 8.87E + 04)
697.51, 26.95
1.19E + 93 (1.36E + 33, 1.05E + 153) 2.39E + 93, 2.71E + 33

Table 2

2.07 (1.23, 2.91)
0.29 (0.14, 0.44)
2.95 (1.99, 3.93)
2.6 (1.78, 3.42)
0.48 (0.32, 0.65)
0.24 (0.06, 0.41)

5.71E + 06 (10.5E + 04, 3.11E + 09)
9.24 (3.04, 28.02)
4.28E + 09 (3.04E + 06, 6.04E + 12)
2.98E + 08 (6.60E + 05, 1.34E + 11)
37.14 (10.95, 125.96)
5.82 (1.53, 22.12)

1.14E + 08, 2.10E + 04
17.97, 5.54
8.56E + 10, 6.07E + 06
5.96E + 08, 1.32E + 06
73.77, 21.39
11.12, 2.43

THC Δ9 tetrahydrocannabinol, CBG cannabigerol, Am American, NH non-Hispanic, RR relative rate, CI 95% confidence interval

cannabinoids which have been noted to be neurotoxic with
effects on foetal brain development including microcephaly, anencephaly and impaired child neurological development [8, 42–45]. Given historically very different and
well-established rates of cannabis use by ethnic groups,

two-stage panel and geospatial regression techniques have
been utilized to carefully adjust for these effects.
Spatiotemporal regression studies implicate both ethnic
and drug exposure variables as being significantly associated with autism incidence with three ethnicities, Caucasian-American, Asian-American and American-Indian and
Alaskan-Native Americans, three drugs, tobacco, alcohol
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Table 5  List of E-Values
No

E Value Estimates

Lower Bound E Values

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Infinity
Infinity
Infinity
Infinity
5.90E + 136
2.39E + 93
2.40E + 65
1.22E + 52
1.20E + 41
9.65E + 29
2.19E + 27
2.50E + 16
3.85E + 15
8.56E + 10
5.96E + 08
1.14E + 08
1.21E + 04
2.77E + 03
990.59
959.59
697.51
73.77
17.97
12.44
11.12
1.33
1.12
1.10
1.08

Infinity
2.40E + 137
5.10E + 129
4.37E + 77
1.88E + 41
2.71E + 33
6.51E + 24
2.40E + 22
4.50E + 20
4.77E + 09
4.50E + 09
6.07E + 06
1.32E + 06
9.40E + 05
2.10E + 04
1.07E + 04
28.51
26.95
25.11
21.39
10.78
10.07
5.54
2.43
1.91
1.18
1.10
1.08
1.05

abuse or dependence, and two cannabinoids, Δ9THC and
cannabigerol, remaining in final models with high levels of
statistical significance when ethnic cannabis use is included
as instrumental variables. When ethnic cannabis use is
included as covariates, all five of them remain significant
in final models.

Table 6  Geospatial Regression
of Dichotomized Legal Status

Application of the techniques of causal inference to this
dataset indicate that the cannabis–autism association satisfies the criteria for causality.
Geospatial analysis confirmed the previously demonstrated increased rate of autism in states where cannabis is
legal.
Of importance, effect size studies demonstrated that
the relationship between both Δ9THC and cannabigerol
and autism is exponential and powerful enough to induce
the seismic paradigm shift which has been observed
epidemiologically.
One notes also that autism is rising whilst the use of the
classical intoxicants tobacco and alcohol is falling. Since
opioid and cocaine use only impact a small segment of the
community, this naturally impugns cannabis use which alone
is rising dramatically.
Whilst the rise in autism rates has been said to be due to
changes in its rate of diagnosis, careful studies in the USA
have shown that the rise is indeed real beyond simply an
increase in diagnostic suspicion or nosology [9].
Modelling studies based on the final models across both
space and time provide robust epidemiological evidence
of a strong upward exponential association between both
Δ9THC and cannabigerol and the autism rate. Combined
with concordant trends in tobacco, alcohol and cannabis
use (mentioned above) and multiple biological pathways
(mentioned below), and satisfaction of causal criteria, these
strong and consistent findings across both space and time
strongly implicate rising cannabis exposure in the community and in pregnancy as a primary underlying driver of the
wave of autism and epidemiologically support our opening
hypotheses.
Whilst cannabis was only used more than 3 days per
month by 7.35% of the population in 2017, high intensity
cannabis use has grown dramatically across the USA in the
past decade with overall daily or near daily use doubling
nationwide [39] and having increased from 0.38 to 1.5%
in the > 35 years cohort 2002–2017 (Fig. 3 [12]). As part
of increased use, the rate of cannabis exposure during the
first trimester of pregnancy is growing steeply as cannabis
use in the wider population increases. Furthermore, women
are having their children later and in so doing are moving

Parameters

Model

Parameter

Estimate

95% CI

P Value

LogLik

Parameters

Value

P value

Spatial spreml Model
Liberal Legal Status

0.0938

(0.02–0.16)

0.0085

191.68

phi
psi
rho
lambda

9.8E-06
0.9508
– 0.8141
0.0938

NA
< 2.2e-16
< 2.2e-16
< 2.2e-16

CI 95% Confidence Interval, LogLik Log likelihood ratio at model optimization
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into older cohorts with cannabis users having a longitudinal
history of greater cumulative cannabis exposure. It is noted
due to the long half-time of cannabis retention and excretion from body fat stores in regular cannabis smokers that
first trimester exposure will occur almost inevitably even if
the mother stops cannabis consumption upon receiving a
diagnosis of pregnancy [46, 47].
In this sense, therefore, the present rapid increase in
numbers presenting with child autism is occurring against a
background of sociodemographic trends in the wider community where high intensity cannabis use is becoming more
common.

Mechanisms
That cannabis potency and use is increasing, is retained in
tissue for significant periods, and has been shown to have
a number of severely neurotoxic activities particularly on
the developing brain is pertinent. Several reports from CDC
have linked cannabis exposure with anencephalus [43, 44]
with separate data linking it to spina bifida in Canada [42],
microcephaly in Hawaii [45] and adverse child neurological outcomes in Pittsburgh, Toronto and the Netherlands
[8]. A generalized inhibitory effect on cell growth has been
reported [48–51], as have interference with synapse formation by inhibition of neuroligin and neurexin, key partners in
synapse formation and determination [7, 52, 53]; an uncoupling of neuronal mitochondrial oxidative phosphorylation
[54, 55] and of grey–white matter connections [56], and
increase in astrogliosis [47], neuroinflammation [57] and
thus brain aging [58], an inhibition of brain neurogenesis
and thus plasticity [59, 60] and adverse effect on the slit:robo
ratio which is one of the key determinants of the formation
of the exuberant cortex characterizing human beings [61,
62] along with numerous other genetic and epigenetic disruptions [63–66].

Epigenetic mechanisms
Recently, profoundly insightful and deeply meaningful
results from an epigenome-wide association study (EWAS)
of cannabis dependence and withdrawal have been published
[67]. The authors examined the DNA methylation status of
20 cannabis-dependent patients both before and after an
11-week period of documented abstinence and compared
these results with those from a comparable group of cannabis-naïve control patients who were sampled at similar
time points.
The results were of profound importance as relates to
perturbation of normal brain development. Significant hits
were found for the brain, cerebrum, cerebral cortex, head
development, brain size, brain formation, forebrain patterning, proliferation of neural cells, brain neurogenesis,

neuronal morphology, central nervous system development
(139 hits), neuronal outgrowth and brain cell movement.
When major brain receptors were considered, there were
132 hits for the AMPA receptor (GRIA), 165 hits for the
kainate receptor (GRIK), 26 hits for the NMDA receptor
(GRIN), 11 hits for the delta glutamate receptor (GRID),
122 hits for the metabotropic glutamate receptor (GRM),
125 hits for the GABA-A receptor (GABRA), 22 hits for the
GABA-B receptor (GABRB), 85 hits for the serotonin receptor (HTR), 17 hits for the dopamine receptor (DRD1), 52
hits for the dopamine transporter (DAT, SLC6A3), 7 hits for
the oxytocin receptor (OXTR), 5 hits for the μ-opioid receptor (ORPM1) and 5 hits for the δ-opioid receptor (ORPD1).
14 and 8 hits were noted for Down syndrome cell adhesion molecule (DSCAM) and discs large homolog associated
protein 2 (DLGAP2) which have both been previously linked
with autism [68–70].
As noted above, the exuberant outgrowth of the human
cortex has been causally attributed to the slit–robo system.
There were 351 hits for slits and 40 hits for robo. Additionally, there were 8 hits for a slit–robo Rho activating GTPase
activating protein 2 (SRGAP2).
It has also been shown that the exuberant frontal outgrowth of the human cortex can be attributed to a steep gradient of the key human morphogen retinoic acid [71, 72].
A high concentration of this key transcription factor at the
frontal pole fell to low levels at the premotor cortex. Indeed,
forced expression of this gradient in the mouse reproduced
the high number of cells seen in the human neocortex in the
murine model [71]. The high frontal concentration of retinoic acid was maintained by an isoform of alcohol dehydrogenase (ALDH1), the lower premotor cortical level was controlled by metabolism by enzymes of the cytochrome system
(CYP26B1) and the retinoic acid signal was transduced by
the key retinoid receptors RXRA and RARB. There were
13 hits in the Schrott dataset for the enzymes of the ALDH1
system (including cadherin 8 and protocadherin 17), 10 hits
for the cytochromes of the CYP2 series, and 9 hits for the
retinoid receptor group.
While these very impressive and stunning results do not
formally prove the salience of epigenomic results in the
aetiology of cannabis-associated congenital brain damage,
they do strongly imply that such data is highly pertinent and
likely to at least partly contribute to meaningful and detailed
explanatory and causal mechanisms which manifest clinically as the autistic spectrum of disorders.

Causal inference
Some comments on the use of the techniques of causal inference in this study are in order. As mentioned in “Methods”,
all mixed effects and robust regressions were performed
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with inverse probability weighting. This is the technique of
choice in causal modelling, which has the effect of making
an observational group broadly comparable across its subgroups, an effect which greatly increases the power of the
study from being purely observational in nature to a pseudorandomized study which has been shown to produce analytical results similar to those found in formal randomized
controlled trials [73]. Hence the use of such inverse probability controlled modelling, especially using several regression techniques (here mixed effects and robust), allows us to
be confident that the results reported are indeed of a causal
nature and not simply associational as may otherwise be
mistakenly assumed.
Secondly, we used the technique of E-values widely
throughout the linear, mixed effects and spatial models
which were reported. E-values quantitate the degree of association required of some hypothetical confounder covariate with both the exposure of interest and the outcome of
concern to explain away an apparently causal relationship.
The scale of the extraordinarily high E-values reported in
this study is unprecedented in the autism literature to our
knowledge. As noted in “Results”, we found that the median
E-value estimate was very high 5.96 × 108 and of the lower
bound of the E-values was 1.07 × 104. Five E-value estimates were infinite and one minimum E-value was infinite.
E-values of this extremely high magnitude clearly discount
the realistic possibility that the reported results may be due
to some extraneous and unidentified confounder covariate
[29, 30, 74–76]. It may be that the very high magnitude of
the E-values reported in the present study reflect the very
large sample size.
Combining inverse probability weighting, E-values, various forms of regression techniques along with the study of
the association in its native space–time context provides
several strong lines of analytical epidemiological evidence
that the relationship reported is real in nature, powerful in
its effect, and amply satisfies the quantitative criteria for
epidemiological causality.

Strengths and limitations
The present study has a number of strengths and limitations.
Its strengths include the use of several nationally representative databases, the application of geospatial and causal inference analytical techniques to these questions for the first
time to our knowledge, the timeliness of the information
presented, the cultural and community-wide implications
at a time when cannabis use is expanding rapidly the use
of multiple forms of regression including space–time studies and the use of the formal and quantitative techniques of
causal inferential modelling. The limitations of the present
study relate mainly to its ecological design which include the
lack of individual participant-level data. In the present study,
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community cannabis use was used as a surrogate marker
for parental cannabis use, as there is no direct database of
which we are aware which links these covariates directly,
and as the cannabis use of pregnant women has been shown
to follow community cannabis use in several studies [35,
36, 38, 77–79]. The findings of this exploration of these
wide-ranging studies are, however, provocative and indicate
further research in this area.

Generalizability
Given that the data we have employed come from the USA,
which by many metrics is reflective of other Western countries, the study findings are likely to be generalizable to other
nations. Whilst there are to our knowledge no other similar
wide-ranging analyses of autism, adverse reports of neurological function following widespread cannabis use have
issued from other countries such as Egypt, China, India and
Morocco [39].

Conclusions
Our results implicate both Δ9THC and cannabigerol in these
studies, which suggest that merely lowering the Δ9THC content of widely available cannabinoid preparations would not
constitute a sufficient public health response. These data
including geotemporospatial analysis and pseudo-randomization of an observational population confirm our opening hypothesis that increased cannabis use and its related
socioethnodemographic trends is one of the principal causes
and primary drivers of escalating US autism rates. The issue
of the exponential relationship between exposure to the cannabinoids Δ9-tetrahydrocannabinol and cannabigerol is of
particular concern and necessarily implies a non-linear,
and in a public health sense, apparently abrupt relationship
between exposure and downstream consequences, which
would be consistent with multiple mechanistic pathways. In
view of the present aggressive growth phase of the emerging
cannabis industry, further research on the factors identified
in this ecological study, including higher definition spatiotemporal epidemiological studies, are indicated.
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